

# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Adolescent Use of Insulin and Patient-Controlled Analgesia Pump Technology: A 10-Year Food and Drug Administration Retrospective Study of Adverse Events**

Judith U. Cope, Audrey E. Morrison and Joy Samuels-Reid

*Pediatrics* 2008;121:e1133-e1138

DOI: 10.1542/peds.2007-1707

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://www.pediatrics.org/cgi/content/full/121/5/e1133>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2008 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



# Adolescent Use of Insulin and Patient-Controlled Analgesia Pump Technology: A 10-Year Food and Drug Administration Retrospective Study of Adverse Events

Judith U. Cope, MD, MPH<sup>a</sup>, Audrey E. Morrison, RN, BScN<sup>a</sup>, Joy Samuels-Reid, MD<sup>b</sup>

<sup>a</sup>Division of Postmarket Surveillance, Office of Surveillance and Biometrics, and <sup>b</sup>Division of Anesthesiology, General Hospital, Infection Control and Dental Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland

The authors have indicated they have no financial relationships relevant to this article to disclose.

## What's Known on This Subject

Infusion pumps are a growing technology that is becoming more widely used in the adolescent age group. Insulin pumps may offer a tighter control of blood glucose. Patient-controlled analgesia pumps deliver pain medications with continuous infusion and programmable features.

## What This Study Adds

This study examines 10 years of FDA adverse event reports with the use of insulin and PCA pumps in the adolescent age group. Concerns about the use of this technology in the 12- to 21-year age group are discussed.

## ABSTRACT

**OBJECTIVES.** From January 1, 2005, through December 31, 2005, the Food and Drug Administration received 5 adolescent death reports associated with the use of insulin pumps, raising concerns about use of this device in this age group. To understand better the types of infusion pump–related problems in adolescents, we performed a comprehensive evaluation of insulin and patient-controlled analgesic pump–related adverse events reported for adolescents that were received by the Food and Drug Administration from 1996 to 2005.

**METHODS.** A search for medical device adverse event reports from January 1, 1996 through December 31, 2005, involving insulin pumps or patient-controlled analgesic pumps used by patients who were aged 12 to 21 years was conducted in the Food and Drug Administration's Manufacturer and User Facility Device Experience Database. Reports were reviewed for demographic characteristics, type of adverse event, and patient morbidity, and potential contributory factors were classified from narratives in the reports.

**RESULTS.** A total of 1674 reports were identified: 1594 for insulin pumps and 53 for patient-controlled analgesic pumps. In reports of insulin pump events, there were 13 reported deaths, 2 reports that indicated possible suicide attempts, and several additional reports indicating severe hypoglycemic or hyperglycemic events that seemed to be device-related. A total of 102 (6.4%) insulin-pump reports highlighted factors that may have contributed to the adverse event, including problems associated with compliance, education, sports-related activities, and dropping or damaging the pump. Eighty-two percent of cases involving the insulin pump resulted in hospitalization. Half of the reports involving patient-controlled analgesic pumps indicated that the patient received an excess of medication; tampering and noncompliance were evident in some cases.

**CONCLUSIONS.** Adolescents are a special population who deserve careful consideration of risk and benefit for use of device technology. Studies need to further identify safety problems in this age group.

[www.pediatrics.org/cgi/doi/10.1542/peds.2007-1707](http://www.pediatrics.org/cgi/doi/10.1542/peds.2007-1707)

doi:10.1542/peds.2007-1707

### Key Words

medical devices, adolescent, infusion pump, diabetes, analgesia, adverse events, postmarket surveillance

### Abbreviations

PCA—patient-controlled analgesia  
 FDA—Food and Drug Administration  
 PMA—premarket approval  
 DKA—diabetic ketoacidosis  
 MAUDE—Manufacturer and User Facility Device Experience

Accepted for publication Oct 1, 2007

Address correspondence to Judith U. Cope, MD, MPH, Office of Pediatric Therapeutics, FDA, Parklawn Room 13B45 HFG-2, 5600 Fishers La, Rockville, MD 20850. E-mail: [judith.cope@fda.hhs.gov](mailto:judith.cope@fda.hhs.gov)

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275); published in the public domain by the American Academy of Pediatrics

**I**NFUSION PUMPS are a growing technology that has been used predominately in the adult population but that has in recent years become more prevalent among adolescents. Large population-based studies have shown high rates of preventable adverse events among hospitalized children,<sup>1</sup> notably adolescents.<sup>2</sup> Miller et al<sup>1</sup> studied pediatric adverse events by using patient safety indicators and found that both young adolescents, aged 10 to 14, and older adolescents, aged 15 to 19, experienced the highest rates of in-hospital adverse events, with older adolescents experiencing nearly twice the adverse event rate of younger group (odds ratio: 1.9; 95% confidence interval: 1.7–2.0). Adolescents who have diabetes may experience device-related problems for a variety of reasons that vary

with patient and disease characteristics.<sup>3</sup> Few studies have examined device-related problems for patient-controlled analgesia (PCA) pumps.

From January 1, 2005, through December 31, 2005, the Food and Drug Administration (FDA) received 5 death reports in which teenage insulin pump users may have been negligent or noncompliant with the use of the device. This prompted a review of infusion pump-related adverse events in this age group to understand better the scope, severity, and type of circumstances described in reports.

It is important to understand the regulatory background and context for which pump devices are used. The majority of insulin pumps that are used for treatment of diabetes are cleared by the FDA through the 510(k) or premarket notification process. The 510(k) process is one type of regulatory pathway for medical devices to enter the market. It allows a manufacturer to show substantial equivalence to a previously approved and marketed device.<sup>4</sup> Alternatively, marketing approval may be obtained by demonstrating with reasonable assurance that the device is safe and effective for its intended use through premarket approval (PMA).<sup>5</sup> Many pumps are cleared for use in the general population through the 510(k) process; however, some pumps, such as implantable pumps, are approved through the PMA process. The PMA is the most stringent type of device marketing application required by FDA.

An insulin pump may offer tighter control of blood glucose levels while aiming to avoid diabetic ketoacidosis (DKA) and hypoglycemia. Pumps can be programmed to provide insulin at a basal rate and also to deliver meal-time or supplementary bolus doses of insulin. The attainment of normoglycemic levels helps to reduce the risk of complications of diabetes; however, insulin pumps have the potential to overmedicate and undermedicate. For example, insulin delivery may be impeded by a weak or depleted battery, occlusion of the infusion set, or even leakage. In some cases, insulin may precipitate and occlude the needle or tubing, thereby impeding delivery of the drug. Other hazards may result in free-flow or excessive insulin administration, putting patients at risk for hypoglycemia.<sup>6</sup>

There are many device components, such as hardware and software, that can contribute to the delivery system and proper device function. If the device should malfunction, then this may result in overinfusion, underinfusion, or delivery of a lethal dose of insulin. Errors associated with filling, refilling, or changing dosage or concentration of the product delivered by the device may also lead to problems of overdelivery or underdelivery of drugs. Other critical issues that should be considered are the accuracy of the software (eg, telemetry), accuracy of dosage calculation, and accuracy of programming the device. Catheter-related problems, such as kinking, leakage, and blockage, may compromise patient outcome. In some implantable pumps, migration may occur, and blockage may also result from marked fibrosis and tissue growth at the implantation site, necessitating removal of the device.

The genesis for PCA pumps was a result of the quest

for more effective pain treatment. PCA technology has evolved and is not restricted to a single class of analgesics or single mode of administration. The pumps deliver intravenous, subcutaneous, and epidural infusions. Patients do not have to wait for administration of their medications by a nurse and may self-administer narcotic analgesia as prescribed by their physician. The two most prevalent modes of administration found in PCA pumps are demand dosing, which delivers a fixed, self-administered dose intermittently, and a fixed-rate background continuous infusion with supplemental patient demand dosing. Most pumps offer both modes with programmable features that allow the pumps to be adjusted by clinicians, who can adjust the bolus size, lockout intervals, and continuous rate infusion. The greatest hazard to patients is increased risk for overmedication, particularly narcotic overinfusion that may lead to respiratory depression. PCA pumps differ in the methods used to store and deliver medication and hardware and software designs. Pumps can be worn, attached to an intravenous pole, or placed at the bedside.

## METHODS

The FDA's medical device adverse event reports database was searched for all reports of insulin pumps and PCA pumps, for patients aged 12 to 21, that were received from January 1, 1996, through December 31, 2005. The database, also known as the Manufacturer and User Facility Device Experience (MAUDE) system, includes all mandatory and voluntary adverse event reports involving medical devices that are submitted to the FDA.<sup>7</sup> The FDA requires manufacturers and user facilities to report adverse events whenever a death or serious injury was or may have been attributed to a medical device or when a medical device was possibly related to a death or serious injury, including events occurring as a result of device failure, malfunction, improper or inadequate device design, manufacturing, labeling, or user error (21 CFR §803.3). Information from these reports is entered into the FDA's MAUDE database.

All reports were identified by using codes specific for insulin or PCA pumps, and duplicate reports were merged. Data were reviewed and evaluated for all reports by using the narrative text and the summary patient or device problem codes indicating the overall nature of the device or patient problem as described by the reporter. For example, with insulin pumps, a patient problem code indicating "hypoglycemia" or "low blood glucose" would be assigned to a report indicating that the patient received too much insulin and experienced a low blood sugar. When summarizing the total number of reports with hypoglycemic complications, we included reports that had more or less of the following patient problem codes: hypoglycemia, low blood glucose, overmedication, insulin shock, and overdose. Reports that were classified as hyperglycemia were identified by using codes for hyperglycemia, undermedication, and underdose. Severe complications as indicated by patient problem code or text indicating DKA, coma, and seizures were also assessed. Reports were further reviewed for the types of injury or malfunction. Details of patient

**TABLE 1** FDA Adverse Event Reports for Insulin Pumps in Adolescents, Aged 12 to 21 Years, January 1, 1996, through December 31, 2005

Parameter	n (%)
Total (n = 1594 reports)	
Males	637 (40.0)
Females	934 (58.6)
Unknown	23 (1.4)
Types of events (n = 1594 reports)	
Injuries	1038 (65.1)
Malfunctions	528 (33.1)
Other events	15 (0.9)
Deaths	13 (0.8)

Source of reports: 1562 manufacturer, 31 voluntary, 1 distributor, 0 user facility.


problems in the narrative text allowed us to group further the types of adolescent issues into the following categories: education, noncompliance, sports and other activities, device misuse, risk-taking behaviors, responsibility and care of the device, pubertal growth, problems occurring while away from home, and lack of parental supervision. Reports were classified as “noncompliance” when the text described that the adolescent failed to keep parent(s) informed, failed to follow diabetic protocol and report problems to caregiver, failed to provide adequate feedback, and was negligent in caring for the device. Reports that were classified in the education category revealed that the adolescent was unfamiliar with the device and its operation and how to troubleshoot. Reports that were classified in the risk-taking category had narrative text describing instances of alcohol abuse, stress, and possible suicidal attempts.

Adverse event reports for PCA pumps were similarly reviewed. Complications that were associated with narcotic use and narcotic drug-related adverse effects were also evaluated.

## RESULTS

### Insulin Pumps

From January 1, 1996, through December 31, 2005, there were 1594 FDA adverse event reports for patients aged 12 to 21 (Table 1). Almost all (n = 1562; 98.0%) were manufacturer reports. During this 10-year period, the annual number of insulin pump reports to the FDA for adolescents increased; since 2003, there was a greater



**FIGURE 1**

FDA adverse event reports for insulin pumps, aged 12 to 21, 1996–2005. Death reports: n = 5 in 2005; n = 4 in 2004; n = 1 in 2003; n = 2 in 2001; n = 1 in 2000.

**TABLE 2** 102 Insulin Pump Reports (6.4%) Indicating Special Adolescent Issues That May Have Contributed to the Adverse Event

Parameter	n
Total no. of cases	102
Males	42
Females	59
Gender not reported	1
Age, mean y	15.8
No. hospitalized	82
Adolescent issues	
Education	47
Noncompliance	19
Both education and noncompliance	2
Sports and other activities <sup>a</sup>	12
Device misuse	8
Risk-taking behaviors <sup>b</sup>	4
Responsibility and care of the device (irresponsible/negligent in care of device)	5
Pubertal growth <sup>c</sup>	3
Occurred when away from home	1
Lack of parental supervision	1

<sup>a</sup> Activities: 3 swimming; 1 each for sailing, bowling, snowboarding, jogging, basketball, football, baseball, biking, and horsing around).

<sup>b</sup> Two possible suicide attempts.

<sup>c</sup> Size, growth spurt, and musculature.

proportion of patient injuries than device malfunctions (Fig 1). A total of 499 (31.3%) adverse event reports were received in 2005. Of these, 381 (76.4%) were patient injuries and 109 (21.8%) were device malfunctions. There were a total of 13 insulin pump-related deaths (8 females, 5 males; mean age: 16.0 years). Reported deaths were related to either hyperglycemic or hypoglycemic complications (n = 5), DKA (n = 3), seizure (n = 1), or coma (n = 1), and 3 death reports did not indicate a cause. Five deaths occurred at home. Three deaths occurred at times when parental supervision was lacking (1 away at college; 1 while the usual family caregiver was away; 1 patient, aged 19 years, was cared for by the adolescent’s spouse).

There were 987 (61.9%) reports with patient problems of hyperglycemia, and 46.6% of these indicated that the patient had DKA. Seventy-three (7.4%) of the 987 reports revealed problems of underinfusion. In these reports, the device problems included error messages (n = 55), incorrect use (n = 24), alarm problems (n = 29), loosening and/or occlusion of the catheters (n = 22), bent cannula (n = 22), and screen display problems (n = 14). There were also 31 reports of the device’s need for repair, replacement, or removal and 19 reports of device failure and/or failure to deliver.

A total of 167 (10.5%) reports included patient and device problems with hypoglycemia or overdelivery of insulin. Several reports were coded as overmedication (n = 15; 17.5%), overdose (n = 7; 4.2%), and insulin shock (n = 1; 0.6%). Device codes also indicated incorrect use of the device (n = 18), problem with self-activating key and overbolusing (n = 9), error message (n = 8), and alarm problems (n = 8). In 60 (35.9%) of the 167 reports, the device problem was coded as unknown.

**TABLE 3** FDA Adverse Event Reports for PCA Pumps in Adolescents, Aged 12 to 21 Years, January 1, 1996, through December 31, 2005

Parameter	n (%)
Total reports aged 12–20 y	53 (100.0)
Males	28 (52.8)
Females	25 (47.2)
Outcome or adverse event type	
Death (2 postoperative, 2 sickle cell disease, 1 severe Demerol reaction)	5 (9.4)
Injury	19 (35.8)
Malfunction	21 (39.6)
Other event	8 (32.0)
Indication for use	
Orthopedic	8 (15.1)
Sickle cell disease	8 (15.1)
Cancer	7 (13.2)
Pregnancy-related	7 (13.2)
Abdominal surgery	3 (5.7)
Other (2 other postoperative, 1 renal, 1 cholecystitis, 1 gunshot)	5 (9.4)
Unknown or not enough information	15 (28.3)

Source of reports: 41 manufacturer, 8 user facility, and 4 voluntary.

In 102 (6.4%) reports, special adolescent issues were identified (Table 2). Eighty-two (80.4%) of the 102 reports resulted in hospitalization. The top 3 issues that were associated with these reports were education, noncompliance, and problems during sports or other activities. Four reports indicated risk-taking behaviors (including 2 reports of insulin overbolusing that were thought to be suicide attempts).

#### Adverse Events for PCA Pumps

A total of 53 reports of adverse events were associated with PCA pumps, including 5 deaths, 19 injuries, 21 malfunctions, and 8 other events (Table 3). In most cases, the device was used to treat pain associated with orthopedic conditions, cancer, sickle cell disease, and pregnancy-related events.

Five death reports included a 19-year-old woman who died of overdosage and overmedication of morphine after cesarean section, a 12-year-old boy who died of an adverse drug reaction to Demerol, a 14-year-old girl who died of overdosage of Dilaudid after surgery, and 2 other adolescents who died during hospitalization for pain control of sickle cell crisis. Twenty-seven (50.9%) reports indicated that the patient received an excess dose of medication (overinfusion, overdosing, overmedication, or overdosage). Twelve of the 27 reports described respiratory depression and unresponsiveness that required ventilation and/or Narcan administration. There were 2 reports of adolescents who had tampered with their PCA pump and successfully removed morphine from the device and 1 report of an adolescent who smoked marijuana while using the pump.

## DISCUSSION

### Insulin Pumps

Within the 10-year study period, we found >1500 unique reports of insulin pump-related adverse events among adolescent users. Although this large number of reports may reflect the expanding use in the pediatric age group,<sup>8</sup> the unique challenges posed by adolescent users should be considered. It is widely recognized that tight control of glucose levels can be used to achieve lower hemoglobin A<sub>1c</sub> levels. Any insulin treatment modality, including delivery of insulin via pump, may be used to achieve this goal. Good glycemic control of diabetes during childhood and adolescence minimizes the risk for microvascular complications in adulthood,<sup>9</sup> and intensive insulin pump therapy may provide an effective alternative to repeated insulin injection therapy by lowering hemoglobin A<sub>1c</sub><sup>9</sup> and allowing for continuous adjustment with added bolus features<sup>10</sup>; however, few studies have closely examined the safety issues for teenage patients. It is known that control of blood glucose often deteriorates during puberty<sup>11,12</sup> and that chronically ill adolescents may be more difficult to treat medically than younger children with the same illnesses.<sup>13,14</sup> Whereas some investigators<sup>15,16</sup> support the use of insulin pumps for adolescents with frequent episodes of DKA, others caution about the risks of both hypoglycemic and hyperglycemic events with pump therapy.<sup>17,18</sup> Although we recognize that the method of insulin delivery, as well as other confounders, plays a role, we think that understanding device-related problems in the adolescent age group is important. Our data indicated that nearly two thirds of FDA reports revealed problems with hyperglycemia. Boland et al<sup>8</sup> conducted a nonrandomized trial comparing insulin pump therapy and repeated injections in a cohort of 75 adolescents who were followed for 12 months with assessments of glycemic control, psychological variables, coping, and adverse events (severe hypoglycemia or DKA). They found that both groups were similar in quality of life, psychological profiles, and depression but noted that those who used infusion pumps experienced fewer severe hypoglycemic events.<sup>8</sup> Bode et al<sup>19</sup> also supported that infusion therapy brings about a decrease in hypoglycemic problems, whereas other studies found that continuous subcutaneous insulin infusion showed high variability in blood glucose control.<sup>20–23</sup> Ahern et al<sup>24</sup> studied 161 children (including 59 adolescents) and found improved diabetes control but not statistically significantly fewer episodes of hypoglycemic events for the adolescent age group.

Although insulin pumps may mimic physiologic insulin replacement, they may be problematic because of adolescent lifestyle and psychosocial factors.<sup>3</sup> Adolescent-aged issues were implicated in many of the FDA reports. We noted several adverse events related to extracurricular activities and accidental dropping and breaking of the pump. This was also reported by Burdick et al<sup>25</sup> in a study of 48 adolescents who received insulin pump therapy: 52% reported disconnecting their pump for exercise. A Finnish study of adolescents with diabetes revealed that 75% believe that they had satisfactorily

complied with the protocol, whereas, on review, only one fifth had actually complied.<sup>26</sup> This study pointed out that teens tend to give health care providers answers that were compliant with expectations and identified conflicts between the adolescent and parents or other caregivers about diabetic care. Better diabetic control among adolescents has been associated with greater parental involvement.<sup>27</sup> The FDA reports revealed 3 deaths that occurred at times when there was no parental supervision.

Difficulties may also arise when teens are careless or tamper with their medical devices, injuring themselves. An increased risk for hypoglycemic complications may occur with binge drinking of alcohol. In our study, a patient who was away at college was found dead in his dorm room after being out with friends the night before. Teenagers with chronic medical disorders have an increased risk for stress and behavioral and psychiatric disorders.<sup>28,29</sup> Two hospitalized patients with diabetes in our series overbolused with insulin, and the reports indicated that these may have been suicide attempts. A review of the literature revealed a case report of a 14-year-old girl who administered hair conditioner through her intravenous infusion pump and died.<sup>30</sup> It is unclear whether her death was attributable to risk-taking behavior or an intentional suicide. Healthcare providers should be aware of possible suicidal ideation among teens with diabetes and potential risks with misuse of medical devices.

Only a few studies have evaluated insulin pump malfunctions that occurred in adolescent patients. A retrospective study of 6 adolescents found 1 teen hospitalized on 2 different occasions for DKA associated with device malfunction.<sup>16</sup> Weintrob et al<sup>31</sup> conducted a small study of 20 adolescent patients and found a higher number of ketotic events for pump users ( $P = .003$ ), all related to infusion set problems. In another study, Saha et al<sup>32</sup> reported that 3 adolescent pump users experienced ketoacidosis related to disconnection and occlusion of the infusion catheters. Our study found that one third of all pump-related problems were malfunctions, and detailed information reported various device problems with error messages and problems with the alarm, catheter, and screen display.

### PCA Pumps

PCA pumps have become an important strategy in pain management for pediatric medical conditions. Although the delivery of opioids has been shown to be effective for pain relief,<sup>33</sup> their administration carries the risk for respiratory depression. In our study, we found 12 cases of respiratory depression that required medical intervention. Two studies in the literature also reported older children and adolescents who experienced problems with oxygen desaturation.<sup>34,35</sup> In our series, more than half of the adverse events indicated that the adolescent received an excess bolus of opioid. In most of the reports, it was unclear whether incorrect dosage boluses, programming errors, drug errors, or accidental bolus administration had occurred. Although studies do indicate that age affects opioid dosing<sup>36</sup> few have discussed the human

factor issues surrounding the use in the adolescent age group. In a pediatric case series of PCA use among patients with sickle cell disease, Shapiro et al<sup>37</sup> noted that 1 adolescent tampered with the device as a possible suicidal gesture. We found 2 cases in our series. Three deaths reported to the FDA indicated that the adolescents were found unconscious too late after overdosage of narcotics, and other reports seemed to be near-miss occurrences that would have been lethal if they had gone unnoticed with time delay. Patients with PCA pumps may allow others to push the button on their pump, and this can result in serious consequences and death.<sup>38</sup> This has led to advisories from manufacturers, ECRI Institute, and the Joint Commission on Accreditation of Healthcare Organizations that allowing anyone other than the patient to press the PCA delivery request button is contraindicated.<sup>39</sup> Life-threatening complications of respiratory depression, oversedation and confusion highlight the need for careful selection and monitoring of adolescent patients who receive this device.

### Limitations

There are many limitations to this study. The majority of adverse event reports were submitted by manufacturers. The accuracy and completeness of the reports were not verified by the FDA. By limiting our search to the specific age group (12–21 years), we were unable to capture reports with missing age information. Medical device adverse event reports cannot clearly establish a cause-and-effect relationship of an injury or illness with the device. The recognition of a device-related event is often subjective and imprecise. The reports had insufficient details about patient factors, such as patient compliance, socioeconomic status, medical history, disease severity, duration of disease, history of substance abuse, years of pump use, and developmental stage of puberty. There were no data on use of pump devices and sales in this age group to provide the denominator to calculate incidence rates of adverse events. Adverse event reports for PCA pumps also had missing information regarding the type of analgesia, dosage, diagnosis, and severity of illness.

### CONCLUSIONS

The use of infusion pump technology for the treatment of diabetes and pain management may pose special risks for the adolescent. This article provides a summary of adolescent-related adverse event reports for insulin pump and PCA therapies. Device-related adverse events that occur in this age group are likely to be underreported in the MAUDE database and in the published literature. The precise rates of device-related complications should be further studied and misuse of these devices be further studied in the adolescent population. Health care practitioners, medical care facilities, and consumers are encouraged to report device-related problems through the FDA Medwatch program: [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

## REFERENCES

1. Miller MR, Elixhauser A, Zhan C. Patient safety events during pediatric hospitalizations. *Pediatrics*. 2003;111(6 pt 1):1358–1366
2. Woods D, Thomas E, Holl J, Altman S, Brennan T. Adverse events and preventable adverse events in children. *Pediatrics*. 2005;115(1):155–160
3. Daneman D. Type 1 diabetes. *Lancet*. 2006;367(9513):847–858
4. Food and Drug Administration. Device Advice: Premarket Notification 510(k). Available at: [www.fda.gov/cdrh/devadvice/314.html#intro](http://www.fda.gov/cdrh/devadvice/314.html#intro). Accessed February 29, 2008
5. Food and Drug Administration. Device Advice Premarket Approval (PMA). Available at: [www.fda.gov/cdrh/devadvice/pma](http://www.fda.gov/cdrh/devadvice/pma). Accessed February 29, 2008
6. JCAHO's National Patient Safety Goal for infusion pump free-flow protection: ECRI's assessment *Health Devices*. 2004 Dec;33(12):430–435
7. Food and Drug Administration. Medical Device Reporting. Available at: [www.fda.gov/cdrh/mdr](http://www.fda.gov/cdrh/mdr). Accessed February 29, 2008
8. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. *Diabetes Care*. 1999;22(11):1779–1784
9. White NH, Cleary PA, Dahms W, et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). *J Pediatr*. 2001;139(6):804–812
10. Weinzimer SA, Sikes KA, Steffen AT, Tamborlane WV. Insulin pump treatment of childhood type 1 diabetes. *Pediatr Clin North Am*. 2005;52(6):1677–1688
11. Palta M, Shen G, Allen C, Klein R, D'Alessio D. Longitudinal patterns of glycemic control and diabetes care from diagnosis in a population-based cohort with type 1 diabetes. The Wisconsin Diabetes Registry. *Am J Epidemiol*. 1996;144(10):954–961
12. Pound N, Sturrock NDC, Jeffcoate WJ. Age related changes in glycated haemoglobin in patients with insulin-dependent diabetes mellitus. *Diabet Med*. 1996;13(6):510–513
13. Grey M, Boland EA. Diabetes mellitus (type 1). In: Jackson PL, ed. *Primary Care of the Child With a Chronic Condition*. 2nd ed. St Louis, MO: CV Mosby; 1996:350–370
14. Moreland EC, Tovar A, Zuehlke JB, Butler DA, Milaszewski K, Laffel LM. The impact of physiological, therapeutic and psychosocial variables on glycemic control in youth with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2004;17(11):1533–1544
15. Blackett PR. Insulin pump treatment for recurrent ketoacidosis in adolescence. *Diabetes Care*. 1995;18(6):881–882
16. Steindel BS, Roe TR, Costin G, Carlson M, Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. *Diabetes Res Clin Pract*. 1995;27(3):199–204
17. Davies AG, Baum JD. A decade of insulin infusion pumps. *Arch Dis Child*. 1988;63(3):329–332
18. Knight G. Risks with continuous subcutaneous insulin infusion can be serious. *BMJ*. 2001;323(7314):693–694
19. Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century: strategies for successful use in adults, adolescents, and children with diabetes. *Postgrad Med*. 2002;111(5):69–77
20. Alemzadeh R, Palma-Sisto P, Parton EA, Holzum MK. Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes. *Diabetes Technol Ther*. 2005;7(4):587–596
21. Danne T, Battelino T, Kordonouri O, et al. A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. *Pediatr Diabetes*. 2005;6(4):193–198
22. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. *Diabetes Care*. 2004;27(3):734–738
23. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. *Diabetes Care*. 2005;28(1):15–19
24. Ahern JA, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. *Pediatr Diabetes*. 2002;3(1):10–15
25. Burdick J, Chase HP, Slover RH, et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. *Pediatrics*. 2004;113(3 pt 1). Available at: [www.pediatrics.org/cgi/content/full/113/3/e221](http://www.pediatrics.org/cgi/content/full/113/3/e221)
26. Kyngäs H. Compliance of adolescents with diabetes. *J Pediatr Nurs*. 2000;15(4):260–267
27. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. *Diabetes Care*. 2003;26(4):1142–1146
28. Goldston DB, Kovacs M, Ho VY, Parrone PL, Stiffler L. Suicidal ideation and suicide attempts among youth with insulin-dependent diabetes mellitus. *J Am Acad Child Adolesc Psychiatry*. 1994;33(2):240–246
29. Northam EA, Matthews LK, Anderson PJ, Cameron FJ, Werther GA. Psychiatric morbidity and health outcome in type 1 diabetes: perspectives from a prospective longitudinal study. *Diabet Med*. 2005;22(2):152–157
30. Knight DM, James RA, Sims DN, Bourne AJ, Martin J, Byard RW. Sudden death due to intravenous infusion of hair conditioner. *Am J Forensic Med Pathol*. 1998;19(3):252–254
31. Weintrob N, Benzaquen H, Galatzer A. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. *Pediatrics*. 2003;112(3 pt 1):559–564
32. Saha ME, Huupponen T, Mikael K, Juuti M, Komulainen J. Continuous subcutaneous insulin infusion in the treatment of children and adolescents with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2002;15(7):1005–1010
33. Grass JA. Patient-controlled analgesia. *Anesth Analg*. 2005;101(5 Suppl):S44–S61
34. Doyle E, Robinson D, Morton NS. Comparison of patient-controlled analgesia with and without a background infusion after lower abdominal surgery in children. *Br J Anaesth*. 1993;71(5):670–673
35. McNeely JK, Trentadue NC. Comparison of patient-controlled analgesia with and without nighttime morphine infusion following lower extremity surgery in children. *J Pain Symptom Manage*. 1997;13(5):268–273
36. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. *Pain*. 1996;64(2):357–364
37. Shapiro BS, Cohen DE, Howe CJ. Patient-controlled analgesia for sickle-cell-related pain. *J Pain Symptom Manage*. 1993;8(1):22–28
38. Marders J. PCA by proxy: too much of a good thing. *Nursing*. 2004;34(4):24
39. JCAHO's National Patient Safety Goal for infusion pump free-flow protection: ECRI's assessment of the protection offered by general-purpose, PCA, and ambulatory pumps. *Health Devices*. 2004;33(12):430–435

# Adolescent Use of Insulin and Patient-Controlled Analgesia Pump Technology: A 10-Year Food and Drug Administration Retrospective Study of Adverse Events

Judith U. Cope, Audrey E. Morrison and Joy Samuels-Reid

*Pediatrics* 2008;121:e1133-e1138

DOI: 10.1542/peds.2007-1707

<b>Updated Information &amp; Services</b>	including high-resolution figures, can be found at: <a href="http://www.pediatrics.org/cgi/content/full/121/5/e1133">http://www.pediatrics.org/cgi/content/full/121/5/e1133</a>
<b>References</b>	This article cites 34 articles, 12 of which you can access for free at: <a href="http://www.pediatrics.org/cgi/content/full/121/5/e1133#BIBL">http://www.pediatrics.org/cgi/content/full/121/5/e1133#BIBL</a>
<b>Citations</b>	This article has been cited by 2 HighWire-hosted articles: <a href="http://www.pediatrics.org/cgi/content/full/121/5/e1133#otherarticles">http://www.pediatrics.org/cgi/content/full/121/5/e1133#otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Endocrinology</b> <a href="http://www.pediatrics.org/cgi/collection/endocrinology">http://www.pediatrics.org/cgi/collection/endocrinology</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.pediatrics.org/misc/Permissions.shtml">http://www.pediatrics.org/misc/Permissions.shtml</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://www.pediatrics.org/misc/reprints.shtml">http://www.pediatrics.org/misc/reprints.shtml</a>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

